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The gold standard for assessing treatment effects is the randomized clinical trial. Providers are fortunate to have a robust set of trials with .80 000 participants showing important benefits and reassuring safety of the non-vitamin K oral anticoagulants (NOACs) relative to warfarin for stroke prevention in atrial fibrillation (AF). 1 -4 Based on the consistent findings of these trials, providers can be confident that NOACs will be safe and effective if prescribed and taken in a similar way and by patients comparable with the trials. However, unselected patients differ from those in clinical trials, and the way treatments are prescribed and taken in practice may differ from trials. In a general practice setting, a group of older patients started on warfarin had higher rates of bleeding and of warfarin discontinuation than patients in the recent randomized trials, and the time in the therapeutic range on warfarin was lower. 5 The Food and Drug Administration (FDA) received reports of serious and fatal bleeding events with dabigatran within several months of the medication becoming available in general practice, and the question was raised as to whether dabigatran might be less safe than was observed in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. 6 These concerns have been allayed through highquality observational studies of unselected populations. 6 -8 It is important, however, to be cautious when estimating treatment effects from observational studies, since there is always residual unmeasured confounding. Even using the same Medicare data source, different techniques have led to disparate conclusions, which should call for restraint in conclusions regarding comparative effectiveness and for critical focus on the quality of methods. 8, 9 Nevertheless, these studies provide good examples of the need for and value of observational studies to address the generalizability of trial results. Due to the need for consent and to the selective nature of centres participating in clinical trials, patients enrolled in trials, relative to the general population, tend to be healthier and less likely to have significant cognitive impairment, which is a predictor of worse medication adherence and lower time in the therapeutic range for patients on warfarin. 10 In the case of NOACs, the trial populations were enriched for patients at risk for stroke by CHADS 2 score, so the trial populations are reasonably reflective of the unselected AF population regarding age and stroke risk factors. In this issue of the journal, Camm et al. describe the results of the XANTUS study, which was a registry of 6784 patients with AF treated with rivaroxaban for stroke prevention in Europe, Israel, and Canada. 11 Patients had mean age and CHADS 2 scores of 71.5 years and 2.0, respectively, and more than one-third of patients were over age 75 years. The observed rates of major bleeding, intracranial haemorrhage, ischaemic stroke, and all-cause mortality were relatively low and similar to those in the NOAC trials ( Table 1) . 1 -4,11 The 1-year discontinuation rate of rivaroxaban was 20%, and 79% of patients were on the 20 mg daily dose, while 21% were treated with 15 mg daily. Among 3812 patients with a creatinine clearance ≥50 mL/min, 15% of patients were underdosed (based on ROCKET-AF trial dosing) at 15 mg daily. How should the clinician interpret these results? It is reassuring that safety events such as major bleeding and intracranial haemorrhage were relatively low in a general practice population. Similar to dabigatran, there have been sporadic reports of bleeding events with rivaroxaban; however, this observational study supports the generalizability of the results from the rivaroxaban trial, as was seen with dabigatran. 1 -4,11 It is important to note that even within the general practice population in XANTUS, these patients were not unselected, since there was a focus on cardiology practices for recruitment and patients had to sign informed consent for participation and active follow-up. This is highlighted by the fact that 10 934 patients were screened, and 38% (4149) were excluded. The most common reason was patient decision (1222), but it is unclear if this was based on refusal to take rivaroxaban, as may be seen in an unselected population, or refusal to participate in the study. Although less selective than a clinical trial, this selectivity probably resulted in a lower risk population than a truly unselected patient population. Claims or national administrative data represent a more unselected patient population, relative to a registry such as XANTUS. Given the variable nature of potential data sources for active surveillance, each must be assessed with regard to its 'fitness-for-use' for specific study objectives. During evaluation of data sources for inclusion in the Sentinel initiative, the FDA prioritized assessment of the scope, content, structure, quality, and timeliness of data, as well as the patient population(s), duration of follow-up, and capture of care across all settings. 12 Selection of an approach for measuring major bleeding in the post-market setting depends on the specific analytic objectives and availability of project resources, and each data source has strengths and limitations ( Figure 1) . Important considerations include the timing of available data, the necessary number of events, and acceptable levels of sensitivity or specificity for event capture.
A particularly important design component of the XANTUS registry is the use of systematic event capture using a standard definition combined with centralized adjudication of bleeding events, which is highly specific and sensitive, and, therefore, represents the gold standard for outcomes classification. However, analyses based on adjudicated events are costly and time-consuming, the value of adjudication is controversial, and resource constraints have led to increasing reliance on alternative data sources for event ascertainment. In the USA, ongoing efforts including the Patient-Centered Outcomes Research Institute's PCORNET, the NIH Collaboratory Distributed Research Network, and the FDA's Sentinel Project hold potential to leverage electronic health records and administrative claims resources to streamline large-scale surveillance efforts.
An additional advantage of large claims or electronic health record data sets is increased sample size, which can provide more statistical power to detect small effects, consistency in subgroups, or in scenarios of rare events. Furthermore, inclusion of a geographically diverse patient population from a wide variety of healthcare settings, such as capturing an entire country, as has been done successfully in Denmark and Sweden, may increase external validity of study findings relative to small or single-centre registries. However, it is important to acknowledge that electronic health records and administrative claims are generated for reimbursement and administrative purposes, and their use for research has been secondary. Successful use of these data sources to capture bleeding events depends upon data availability and valid methods for identifying bleeding within a particular setting.
To date, validation of claims-based algorithms to identify bleeding events has demonstrated good performance. 13, 14 An important trade-off is that administrative claims are limited in their ability to support more precise major bleeding event classification, such as events meeting International Society of Thrombosis and Haemostasis (ISTH) major bleeding criteria, and may provide estimates not directly comparable with registries. While information on laboratory values such as a drop in haemoglobin may eventually be accessible through electronic health record queries, fragmented data from laboratory, hospital, and outpatient settings present challenges to ISTH classification. It is alarming to observe that in general practice, the NOACs are systematically underdosed, as was seen in 15% of patients from XANTUS, who did not require a dose adjustment based on creatinine clearance. In the Medicare population, 16% of AF patients treated with dabigatran received the 75 mg dose, while less than a third . Editorial of patients treated with that dose had renal impairment noted in the prior 6 months. 8 In Canada, pharmacy sales data have shown that nearly half of prescriptions for apixaban are for the 2.5 mg dose, which should only be used in 5% of the population meeting two of the three criteria for dose reduction, based on the ARISTOTLE trial. 3 Systematic underdosing is not surprising and appears also to happen with warfarin based on time in the therapeutic range in general clinical practice; 15 however, the degree of underdosing may result in preventable strokes. A common question is whether similar medication treatment effects and adverse events will be seen in general clinical practice, as were seen in clinical trials. With XANTUS, we now have observational data supporting rates of stroke and bleeding that were similar to the NOAC trials, with good persistence of treatment. It does appear that there is systemic underdosing of NOACs, which should be an area of further focus, as underdosing probably results in preventable strokes. Choice of optimal methods for understanding how treatments are used and the related outcomes in general practice depends on the specific objectives and available resources. Registries and administrative claims data provide complementary opportunities, and dedicated efforts are needed to improve the quality and reliability of each with the ultimate goal of improving application of treatments in general practice.
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